Clara Biotech Granted Patent No. 11,162,143 for Novel Isolation and Purification of Exosomes

Clara Biotech, Inc. (Clara), a biotech company based in Lawrence, KS, is pleased to announce that on November 2, 2021, the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,162,143 – METHODS FOR GENERATING THERAPEUTIC DELIVERY PLATFORMS, which covers its technology platform for capture, loading, and photo-release of extracellular vesicles and exosomes. This is one of several patent applications Clara has licensed from the University of Kansas and the Kansas State University Research Foundation.

Exosomes are small vesicles produced by all eukaryotic cells. They are surrounded by a bilayer lipid membrane and typically range in size from 30 – 150 nm. The contents of naturally produced exosomes include nucleic acids such as genomic DNA and various forms of RNA, proteins, and lipids that carry information to other cells, sometimes to cells a great distance from the originating cell.

Jim West, CEO of Clara, stated his excitement about the issuance, remarking, “We are thrilled to expand our patent coverage as we develop the ExoRelease™ technology platform. This patent not only covers our technology but also serves as the core of our platform, unlocking a myriad of opportunities for future diagnostic and therapeutic products. This unique immunocapture and release platform to isolate and purify exosomes will help to enable the next generation of biotechnology.”

Clara currently offers a service to isolate and purify exosomes using this technology and plans to launch a laboratory kit in the near future. The Company intends to support molecular diagnostic and biopharma partners who require pure exosomes.

ABOUT Clara Biotech

Clara Biotech was founded in 2018 by James E West III, engineer, and entrepreneur, and Dr. Mei He, exosome expert and assistant professor at the University of Florida. Clara Biotech has developed novel methods to isolate and purify exosomes. Its non-chemical ExoRelease™ platform uses proprietary immunocapture and release technology to exclusively isolate exosomes. The ExoRelease™ platform provides a simple, repeatable, time-saving protocol and has compatibility with multiple bio-sample types. This yields pure, completely functional, in-tact, and subtyped exosomes. Clara Biotech is in the early stages of commercializing an ExoRelease™ lab kit for Research Use Only.

The original press release can be found here.